股票 › IVBIY
信达生物制药 IVBIY
美股市值排名 #832
$43.55 −$0.45 (-1.02%)
休市 · Nov 7, 3:40 pm ET
开盘$43.70
昨收$44.00
当日区间$42.00 – $43.70
成交量6.00
市值$23.67B
市盈率（TTM）111.7
股息率–
IVBIY 相关新闻
匹配 INNOVENT BIOLOGICS INC UNSPON ADS EACH REP 4 ORD SHS 或代码 IVBIY 的头条新闻，按最新排序。
- INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2026
- Innovent Bio (1801.HK): Interim Results Beat Expectations; High-Quality Growth and Global Expansion Proceed in Tandem; 2030 Strategic Goals Announced for the First Time 正面
- INNOVENT BIO: 2026 INTERIM REPORT
- INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - JAYPIRCA (PIRTOBRUTINIB) APPROVED IN CHINAFOR A NEW INDICATION IN CHRONIC LYMPHOCYTIC LEUKEMIA(CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) ACROSS ALL LINESOF THERAPY 正面
- Innovent Bio (01801.HK): Triple Inflection Points Converge, Triggering Global Revaluation
- Major Broker Ratings | Citi: The "15th Five-Year" Plan for the pharmaceutical industry is favorable to innovative drugs and medical devices; Hengrui Pharma and Innovent Bio are our top picks, among others.
- Innovent Bio (01801.HK): Dual-engine growth driven by oncology and diversified product portfolio sustains strong performance 正面
- Innovent Bio (01801.HK): Results Beat Expectations; Internationalization and Commercialization Accelerate Further 正面
- Innovent Bio (1801.HK): Innovation Leader Competing on the Global Stage
- Innovent Bio (01801.HK): First-half results exceed expectations; 2030 revenue target underscores confidence.
- Innovent Bio (1801.HK): Strong 1H26 Earnings Growth, Revenue Target Nearly Doubled by 2030, Globalization Milestone, Upside to Price Target 正面
- Innovent Bio (01801.HK): Commercialization continues to scale up, and its diversified platform is accelerating the realization of value from its innovative pipeline.
- Innovent Bio (1801.HK): Product volume continues to expand; focus on growth resilience amid a high base. 正面
- INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- [Major Banks] Goldman Sachs Raises Innovent Bio (01801.HK) Target Price to HK$122.28; Q3 Product Sales Meet Expectations 正面
暂无评论——快来第一个聊聊 IVBIY。